Last reviewed · How we verify
ACEI treatment
ACE inhibitors block the angiotensin-converting enzyme, reducing the production of angiotensin II and lowering blood pressure.
ACE inhibitors block the angiotensin-converting enzyme, reducing the production of angiotensin II and lowering blood pressure. Used for Hypertension, Heart failure, Post-myocardial infarction.
At a glance
| Generic name | ACEI treatment |
|---|---|
| Also known as | Control group |
| Sponsor | Children's Hospital of Fudan University |
| Drug class | ACE inhibitor |
| Target | Angiotensin-converting enzyme (ACE) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
ACE inhibitors prevent the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This leads to vasodilation, reduced aldosterone secretion, and decreased sodium and water retention, resulting in lower blood pressure and reduced cardiac workload. They are commonly used in hypertension and heart failure management.
Approved indications
- Hypertension
- Heart failure
- Post-myocardial infarction
- Diabetic nephropathy
Common side effects
- Persistent dry cough
- Hyperkalemia
- Dizziness
- Angioedema
- Hypotension
Key clinical trials
- A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease (PHASE1, PHASE2)
- Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection
- Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN (PHASE2)
- A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria (PHASE3)
- Chaigui Longmu Ejiao Paste for Ischemic Heart Disease (PHASE2)
- The GUARDIAN Pilot Trial (NA)
- A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates
- Baroreflex Activation Therapy for Heart Failure (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACEI treatment CI brief — competitive landscape report
- ACEI treatment updates RSS · CI watch RSS
- Children's Hospital of Fudan University portfolio CI